Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.58 |
| ▸ | CDK2 | P24941 | 9/20 | 0.58 |
| ▸ | CDC7 | O00311 | 9/20 | 0.58 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614242 | 0.84 | ROCK1 (0.66) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL613818 | 0.81 | ROCK1 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL614658 | 0.80 | ROCK1 (0.62) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL612621 | 0.78 | CDC7 (0.62) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL10238474 | 0.78 | CCNE1 (0.48) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL611799 | 0.78 | CDC7 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL611766 | 0.77 | ROCK1 (0.58) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL611750 | 0.74 | CDC7 (0.61) | ROCK1CCNE1CDK2CDC7DBF4 | |
| SCHEMBL3223414 | 0.73 | ENPP2 (0.45) | OPRK1HTR1AADORA3HTR2CSLC6A3 | |
| SCHEMBL614700 | 0.73 | ROCK1 (0.64) | ROCK1CCNE1CDK2CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| US-8691828-B2 | Thienopyrimidine as CDC7 kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | ROCK1 2609/4885CCNE1 158/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.